Industry News

• Accelrys announces latest release of Its leading discovery studio(R) application  Accelrys announced the release of Accelrys Discovery Studio(R)2.5.5, the most advanced computational chemistry and biology software application for drug discovery. This release features new algorithmic developments in the protein modeling area.
  Accelrys, Inc. March 16, 2010  
• Neurocrine Biosciences announces exercise of over-allotment option for common stock   Neurocrine Biosciences announced that the underwriter of its recently completed public offering of common stock has exercised in full its option to purchase an additional 1,365,000 shares of common stock to cover over-allotments with gross proceeds of approximately $23 million.
  Neurocrine Biosciences, Inc. March 16, 2010  
• BioTime reports publication on the reversal of the development  BioTime announced the publication of a scientific paper itled "Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming." The article was released online in the peer-reviewed journal Regenerative Medicine in advance of the print publication.
  BioTime, Inc. March 16, 2010  
• XOMA receives notice of non-compliance from NASDAQ  XOMA announced that it has received a Staff Determination letter from The NASDAQ Stock Market indicating that the company has not regained compliance with the minimum $1.00 per share requirement for continued inclusion on The NASDAQ Global Market, pursuant to NASDAQ Listing.
  XOMA Ltd. March 16, 2010  
• Founder of UCLA's Jonsson Comprehensive Cancer Center dead at 79  Kenneth A. Jonsson, who along with his late wife, Diana, helped to found UCLA's Jonsson Comprehensive Cancer Center, died March 15 at his Pacific Palisades home. He was 79. Jonsson made his first donation to support cancer research more than four decades ago in the 1960s.
  Jonsson Comprehensive Cancer Center March 16, 2010  
• Cytokinetics announces changes to Its board of directors  Cytokinetics announced the resignation of James Sabry, M.D., Ph.D., Co-founder and former CEO, from the company's Board of Directors. Dr. Sabry, who has been serving as Chairman of the Board of Directors, is resigning in order to assume an operational role at a pharmaceutical company.
  okinetics, Incorporated March 16, 2010  
• Cardium reports fourth quarter and year-end 2009 financial results   Cardium Therapeutics reported net income of $9.3 million versus a net loss of $5.1 million for the same period in 2008. Cardium ended the year with cash and cash equivalents totaling $3.4 million compared to $1.1 million the previous year.
  Cardium Therapeutics March 16, 2010  
• Boston Scientific completes enrollment in PLATINUM trials  Boston Scientific announced completion of patient enrollment in the Small Vessel and Long Lesion trials of its PLATINUM clinical program that are designed to compare the platinum chromium PROMUS® Element Everolimus-Eluting Stent System to matched historical control groups of patients.
  Boston Scientific Corporation March 16, 2010  
• Illumina announces HumanOmniExpress+ Custom BeadChip  Illumina unveiled its new HumanOmniExpress+Custom BeadChip, an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up to 200,000 custom variants for a total of >900k variants per sample.
  Illumina, Inc. March 16, 2010  
• ADVENTRX Pharmaceuticals reports fourth quarter and full year 2009 financial results  ADVENTRX reported net loss applicable to common stock for the fourth quarter of 2009 was $6.5 millionversus a net loss applicable to common stock of $7.5 millionfor the same period in 2008. As of December 31, 2009, the Company had cash totaling $8.7 million and working capital of $6.6 million.
  ADVENTRX Pharmaceuticals, Inc. March 16, 2010  

   (next 10 articles)